Guest Specialists



Dr. Amin Asim

Dr. Asim Amin 


AnMed Health Cancer Center hosted Asim Amin, M.D., Ph.D., director of immunotherapy and melanoma at Levine Cancer Institute March 18, 2019. Dr. Amin met with physicians and oncologists and cancer-related clinics and organizations.

Dr. Amin was a principal investigator of early immunotherapy trials and has played a key role in the development of immunotherapy drugs for melanoma.

AnMed Health is a charter member of Levine Cancer Institute’s (LCI) cancer care network, which has a unique model of care, providing communities access to world-class care close to home. LCI members seek to provide local patients with access to internationally-renowned physician expertise. The hybrid model combines academics and oncology research with compassionate, community-based cancer care. For AnMed Health patients, this means access to an expanded clinical team.    

AnMed Health's cancer program is accredited by the Commission on Cancer of the American College of Surgeons. As a CoC-accredited cancer center, AnMed Health takes a multidisciplinary approach to treating cancer as a complex group of diseases that requires consultation among surgeons, medical and radiation oncologists, diagnostic radiologists, pathologists and other cancer specialists.

Dr. Amin received his medical degree from King Edward Medical College. He completed his internal medicine residency at Providence Hospital and fellowship in hematology/oncology at Georgetown University Hospital. Dr. Amin earned his Ph.D. in immunology at the University of California Davis and was involved with development of immunotherapy for cancer using monoclonal antibodies.

Before joining Levine Cancer Institute, Dr. Amin served as a clinical associate professor at the Lombardi Cancer Center at Georgetown University where he led research efforts in renal cell carcinoma and melanoma. Dr. Amin is a clinical associate professor of medicine at the University of North Carolina at Chapel Hill. He is a member of the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer.